Table 1.
The clinical characteristics of bronchoscopy‐guided biopsy tissues and tumor success rate of BDXs in NSCLC
| Patient characteristics | No. of patients | No. of BDXs (%) | No. of no BDXs (%) | P value |
|---|---|---|---|---|
| Total | 114 | 30 (26.32) | 84 (73.68) | |
| Gender | 0.301 | |||
| Male | 90 | 26 (28.89) | 64 (71.11) | |
| Female | 24 | 4 (16.67) | 20 (83.33) | |
| Smoking status | ||||
| Smoker | 69 | 23 (33.33) | 46 (66.67) | 0.010 |
| Non‐smoker | 21 | 1 (4.76) | 20 (5.00) | |
| Histologic type | ||||
| ADC | 37 | 6 (16.21) | 31 (83.78) | |
| SCC | 75 | 24 (32.00) | 51 (68.00) | 0.112 |
| Others | 2 | 0 (0) | 2 (100) | |
| NSCLC pathologic stage | 0.421 | |||
| Stage I | 4 | 0 (0.00) | 4 (100.00) | |
| Stage II | 3 | 2 (66.67) | 1 (33.33) | |
| Stage III/IV | 93 | 26(27.96) | 67 (72.04) | |
| EGFR status | 0.244 | |||
| EGFR MT | 8 | 1 (12.5) | 7 (87.5) | |
| EGFR WT | 55 | 17 (30.91) | 38 (69.09) | |
| KRAS status | 0.518 | |||
| KRAS MT | 2 | 1 (50.00) | 1 (50.00) | |
| KRAS WT | 59 | 17 (28.81) | 42 (71.19) |
Others: large cell lung cancer and unclassified non‐small cell lung cancer (NSCLC). ADC, adenocarcinoma; BDX, biopsy‐derived xenografts; EGFR, epidermal growth factor receptor; KRAS, v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog; MT, mutation; SCC, squamous cell carcinoma; WT, wild‐type.